Benzothiopyran-4-one based reversible inhibitors of the human cytomegalovirus (HCMV) protease

被引：51

作者：

Dhanak, D

Keenan, RM

Burton, G

Kaura, A

Darcy, MG

Shah, DH

Ridgers, LH

Breen, A

Lavery, P

Tew, DG

West, A

机构：

[1] SmithKline Beecham Pharmaceut, Collegeville, PA 19426 USA

[2] SmithKline Beecham Pharmaceut, Harlow CM19 5AG, Essex, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1998年 / 8卷 / 24期

关键词：

D O I：

10.1016/S0960-894X(98)00666-0

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel class of CMV protease inhibitors based on a benzothiopyran-S,S-dioxide nucleus has been discovered. Enzyme kinetic data supports a reversible mode of inhibition for a representative member of this class, 2-(3-pyridyl-N-oxide)benzothiopyran-4-one-S,S-dioxide, 1. Experiments in the presence and absence of the disulfide reducing agent DTT suggest that the inhibition by 1 is not due to oxidative inactivation of the enzyme. Also presented are results of some SAR studies of the benzothiopyranone ring system. (C) 1998 Elsevier Science Ltd. All rights reserved.

引用

页码：3677 / 3682

页数：6

共 21 条

[1] Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation [J].

Baum, EZ ;

Ding, WD ;

Siegel, MM ;

Hulmes, J ;

Bebernitz, GA ;

Sridharan, L ;

Tabei, K ;

Krishnamurthy, G ;

Carofiglio, T ;

Groves, JT ;

Bloom, JD ;

DiGrandi, M ;

Bradley, M ;

Ellestad, G ;

Seddon, AP ;

Gluzman, Y .

BIOCHEMISTRY, 1996, 35 (18) :5847-5855

[2] Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation [J].

Baum, EZ ;

Siegel, MM ;

Bebernitz, GA ;

Hulmes, JD ;

Sridharan, L ;

Sun, L ;

Tabei, K ;

Johnston, SH ;

Wildey, MJ ;

Nygaard, J ;

Jones, TR ;

Gluzman, Y .

BIOCHEMISTRY, 1996, 35 (18) :5838-5846

[3] EXPRESSION AND ANALYSIS OF THE HUMAN CYTOMEGALOVIRUS-UL80-ENCODED PROTEASE - IDENTIFICATION OF AUTOPROTEOLYTIC SITES [J].

BAUM, EZ ;

BEBERNITZ, GA ;

HULMES, JD ;

MUZITHRAS, VP ;

JONES, TR ;

GLUZMAN, Y .

JOURNAL OF VIROLOGY, 1993, 67 (01) :497-506

[4] Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors [J].

Bonneau, PR ;

GrandMaitre, C ;

Greenwood, DJ ;

Lagace, L ;

LaPlante, SR ;

Massariol, MJ ;

Ogilvie, WW ;

OMeara, JA ;

Kawai, SH .

BIOCHEMISTRY, 1997, 36 (41) :12644-12652

[5] Design and synthesis of monocyclic β-lactams as mechanism-based inhibitors of human cytomegalovirus protease. [J].

Borthwick, AD ;

Weingarten, G ;

Haley, TM ;

Tomaszewski, M ;

Wang, W ;

Hu, ZH ;

Bedard, J ;

Jin, HL ;

Yuen, L ;

Mansour, TS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :365-370

[6]

BOSSERT F, 1964, LIEBIGS ANN CHEM, V680, P40

[7]

BRITT K, 1995, VIRODOLOGY, V2, P2493

[8]

Bromme D, 1996, BIOCHEM J, V315, P85

[9] Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad [J].

Chen, P ;

Tsuge, H ;

Almassy, RJ ;

Gribskov, CL ;

Katoh, S ;

Vanderpool, DL ;

Margosiak, SA ;

Pinko, C ;

Matthews, DA ;

Kan, CC .

CELL, 1996, 86 (05) :835-843

[10]

GILCHRIST TL, 1976, J CHEM SOC P1, V20, P2166

← 1 2 3 →